Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.052 AUD | -1.89% |
|
+26.83% | 0.00% |
Jul. 01 | Emyria Receives Grant to Develop MDMA Analog Drug Program; Shares Up 17% | MT |
Jun. 20 | Emyria to Facilitate PTSD Treatment Trial | MT |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Patients
93.4
%
| 1 | 74.2 % | 1 | 93.4 % | +9.94% |
Research Projects and Data Deals
6.6
%
| 0 | 25.8 % | 0 | 6.6 % | -77.57% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | -12.62% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Winlo
CEO | Chief Executive Officer | - | 19-10-02 |
Mary Ann Rennie
COO | Chief Operating Officer | - | - |
Tracie Ernenwein
CTO | Chief Tech/Sci/R&D Officer | - | - |
Lexi O’Halloran
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | - | - | |
Susan Park
SEC | Corporate Secretary | 49 | 23-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mohit Kaushal
BRD | Director/Board Member | 45 | 23-08-20 |
John Tooke
BRD | Director/Board Member | 75 | 18-03-22 |
Karen Smith
BRD | Director/Board Member | 56 | 21-11-28 |
Greg Hutchinson
CHM | Chairman | - | Nov. 20 |
Michael Winlo
CEO | Chief Executive Officer | - | 19-10-02 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 366,629,396 | 245,817,666 ( 67.05 %) | 0 | 67.05 % |
Company contact information
![address Emyria Limited(EMD)](https://cdn.zonebourse.com/static/address/102588375.png)
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
0.00% | 14.43M | |
-35.02% | 13.14B | |
+4.48% | 11.75B | |
-6.31% | 11.22B | |
+8.57% | 10.5B | |
+28.25% | 8.62B | |
-11.77% | 7.09B | |
+12.23% | 7.11B | |
+9.84% | 6.4B | |
0.00% | 4.24B |
- Stock Market
- Equities
- EMD Stock
- Company Emyria Limited